Australia markets closed

Alpine Immune Sciences, Inc. (ALPN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
64.43-0.03 (-0.05%)
At close: 04:00PM EDT
64.42 -0.01 (-0.01%)
After hours: 04:33PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.22B
Enterprise value 3.91B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)54.73
Price/book (mrq)12.88
Enterprise value/revenue 66.36
Enterprise value/EBITDA -124.41

Trading information

Stock price history

Beta (5Y monthly) 1.16
52-week change 3799.86%
S&P500 52-week change 321.23%
52-week high 364.57
52-week low 36.71
50-day moving average 339.08
200-day moving average 320.70

Share statistics

Avg vol (3-month) 32.17M
Avg vol (10-day) 36.74M
Shares outstanding 565.56M
Implied shares outstanding 665.56M
Float 844.93M
% held by insiders 14.65%
% held by institutions 191.41%
Shares short (28 Mar 2024) 45.28M
Short ratio (28 Mar 2024) 44.15
Short % of float (28 Mar 2024) 413.14%
Short % of shares outstanding (28 Mar 2024) 48.06%
Shares short (prior month 29 Feb 2024) 44.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 325 July 2017
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 325 July 2017

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -54.66%
Operating margin (ttm)5.01%

Management effectiveness

Return on assets (ttm)-8.30%
Return on equity (ttm)-12.69%

Income statement

Revenue (ttm)58.88M
Revenue per share (ttm)1.18
Quarterly revenue growth (yoy)1,011.40%
Gross profit (ttm)N/A
EBITDA -43.67M
Net income avi to common (ttm)-32.18M
Diluted EPS (ttm)-0.64
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)327.41M
Total cash per share (mrq)4.99
Total debt (mrq)9.91M
Total debt/equity (mrq)3.02%
Current ratio (mrq)7.86
Book value per share (mrq)5.43

Cash flow statement

Operating cash flow (ttm)-79.01M
Levered free cash flow (ttm)-29.06M